DKSH : Hong Kong and Novartis Hong Kong Forge Partnership to Enhance Healthcare Solutions

Media Release

DKSH Hong Kong and Novartis Hong Kong Forge Partnership to Enhance Healthcare Solutions

DKSH Hong Kong enters a partnership with Novartis Hong Kong, a global pharmaceutical company. This partnership establishes DKSH as the trusted provider of full agency services to Novartis with a shared mission to drive innovation and advance patient care in the local Hong Kong market.

Hong Kong, November 3, 2023 - DKSH's Business Unit Healthcare, a Strategic Healthcare Solutions Partner and leading provider of Market Expansion Services for pharmaceutical, over-the-counter (OTC), consumer health and medical device companies, announces a partnership with Novartis Hong Kong, a global pharmaceutical company that delivers innovative medicines to alleviate society's greatest disease burdens through technological leadership in research and development, and novel access approaches. This collaboration marks a significant step forward in advancing patient care and accessibility in the region.

Renowned for a full range of integrated services to support partners' journey of growth, DKSH Hong Kong has been chosen by Novartis Hong Kong as one of its partners to implement the full agency business model in Hong Kong, delivering innovative healthcare solutions that prioritize the well-being and purpose of patients. With this partnership, DKSH manages a selected range of Novartis products in Hong Kong, encompassing sales, marketing, distribution, and other associated activities.

This partnership with Novartis grants DKSH Hong Kong access to a selection of portfolio of products in the market, covering oncology, immunology, and ophthalmology with over 20 innovative treatments. By leveraging DKSH's extensive distribution network and commercial expertise, the partnership aims to ensure that these life-changing treatments reach a significant number of patients, empowering them with improved options for their healthcare needs.

"We are thrilled to embark on this partnership with Novartis. This collaboration reflects DKSH's commitment to act with purpose and grow with passion, as we strive to provide better solutions for disease management and improve patient outcomes. By combining our expertise and resources with Novartis, we can offer an unparalleled level of healthcare services in Hong Kong," said Wai Ting Fong, Head of Management and Vice President, Healthcare, DKSH Hong Kong & Macau.

"We are excited to partner with DKSH in Hong Kong," stated Derek Chang, Head of Novartis Hong Kong. "This collaboration can enhance access to innovate medicines in both private and public sectors. By joining forces with DKSH, we can leverage their market expertise and expand our reach, ultimately providing more transformative treatments to more patients in Hong Kong."

Novartis Hong Kong partnership with DKSH Hong Kong Business Unit Healthcare not only reinforces DKSH's commitment to its purpose-driven approach but also strengthens its market position in the healthcare sector.

About Novartis Hong Kong

Novartis is a focused innovative medicines company. Every day, Novartis works to reimagine medicine to improve and extend people's lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Novartis medicines reach more than 250 million people worldwide. In Hong Kong, with approximately 100 innovative medicines registered, Novartis products benefit around one million patients each year.

1

About DKSH

DKSH's purpose is to enrich people's lives. For more than 150 years, we have been delivering growth for companies in Asia and beyond across our Business Units Healthcare, Consumer Goods, Performance Materials, and Technology. As a leading Market Expansion Services provider, we offer sourcing, market insights, marketing and sales, eCommerce, distribution and logistics as well as after-sales services. DKSH is a participant of the United Nations Global Compact and adheres to its principles-based approach to responsible business. Listed on the SIX Swiss Exchange, DKSH operates in 37 markets with 32,600 specialists, generating net sales of CHF 11.3 billion in 2022. The DKSH Business Unit Healthcare distributes pharmaceuticals, consumer health and over-the-counter (OTC) products as well as medical devices. With around 7,990 specialists, the Business Unit generated net sales of CHF 5.6 billion in 2022. http://www.dksh.com/hec

For further information, please contact:

DKSH Hong Kong

Sandy Sum

Manager, Marketing & Communications Tel: +852 2895 9610 sandy.sum@dksh.com

2